King buys Elan drugs

Related tags Puerto rico United states

King Pharmaceuticals is to buy the rights to two of Elan Corp.'s
drugs in the United States and Puerto Rico for $850 million.

King Pharmaceuticals is to buy the rights to two of Elan Corp.'s drugs in the United States and Puerto Rico for $850 million.

The purchase includes insomnia treatment Sonata and muscle relaxant Skelaxin, rights to potential new formulations of these products, and Elan's primary care field sales force of more than 400 representatives.

In a press release, Bristol-based King said the acquisition of the Irish pharmaceutical company's unit will add to its earnings upon closing, and noted Sonata and Skelaxin had 2002 sales of about $238 million in the United States and Puerto Rico.

Under the agreement, King will reimburse Elan for the costs of developing new formulations of Sonata, and potentially pay Elan more than $70 million upon achievement of certain milestones, including regulatory approval.

Related news

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us

Products

View more

Webinars